Skip to main content

Table 1 Patient data

From: Anti-N-methyl-D-aspartate receptor encephalitis: the clinical course in light of the chemokine and cytokine levels in cerebrospinal fluid

Patients
Number 1 2 3 4 5 6 7 8 9
Sex F F F F M F F F F
Age of onset (years) 7 10 13 13 13 18 20 18 26
Follow-up (months) 25 12 26 13 1 1 6 12 5
Clinical features at the disease peak
Psychiatric features Yes Yes Yes Yes Yes Yes Yes Yes Yes
Cognitive dysfunction Yes Yes Yes Yes Yes Yes Yes Yes Yes
Seizures Yes No Yes Yes No Yes Yes Yes Yes
Movement disorder Yes Yes No Yes Yes No No Yes No
Autonomic dysfunction Yes No No No No No No Yes No
Coma Yes No No No No No No Yes No
Laboratory features at the disease diagnosis
MRI changes No No No Yes No No No No Yes
EEG changes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Disease course and therapy
Progression (days)a 28 15 28 17 6 16 30 29 29
Time to therapy (days)b 6 15 49 21 4 320 60 21 29
Recovery (days)c 750 43 91 72 30 320 36 150 85
Therapyd IVIG, CS, PE, RTX, CPA, IA, alemtuzumab, MTX, MMF PE, CS, IVIG PE, CS, IVIG PE, CS, IVIG CS, IVIG PE, IVIG, CS CS, IVIG PE, IVIG, CS, RTX PE, CS, CPA
  1. This table summarizes the clinical, laboratory and follow-up data of nine patients with non-paraneoplastic anti-NMDAR encephalitis who were included in this study. Our clinical study was focused on the dynamic course of the disease over time (in days after the onset of the first disease symptom): atime to the peak in disease severity (all of the patients reached their disease severity peak within 30 days, and despite receiving immunotherapy, patients nos. 1 and 8 progressed to a mRS of 5); btime to first therapy administration (all of the patients except for patient no. 6 received therapy within 60 days); and ctime to clinical improvement to a mRS ≤2 (the recovery time varied between the patients: median 85 days, range 30–750 days; patient no. 6 had a mRS of 2 at the time of diagnosis). dThe therapy summary is indicated as follows: CPA cyclophosphamide, CS corticosteroids, IA immunoadsorption, MMF mycophenolate mophetil, MTX methotrexate, PE plasma exchange, RTX rituximab